ANI Pharma (ANIP) Misses Q3 EPS by 20c, Revenues Miss; Offers FY19 EPS/Revenue Guidance Below Consensus
Tweet Send to a Friend
ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $1.23, $0.20 worse than the analyst estimate of $1.43. Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
